Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 3/20 | 0.50 |
| ▸ | KDM4A | O75164 | 2/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.50 |
| ▸ | TET3 | O43151 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRE | P78334 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17726829 | 1.00 | TET2 (0.50) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL29100702 | 0.84 | HDAC3 (0.39) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL29100706 | 0.84 | HDAC3 (0.39) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL28276395 | 0.82 | FOLH1 (0.41) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL9668938 | 0.81 | TSHR (0.43) | MEN1KMT2AGAACYP2D6TSHR | |
| SCHEMBL27416805 | 0.80 | CYP1A2 (0.54) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL27981720 | 0.80 | FOLH1 (0.44) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL764174 | 0.80 | CYP1A2 (0.54) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL27981718 | 0.80 | FOLH1 (0.44) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL11420328 | 0.80 | CYP1A2 (0.54) | TET2KDM4AKDM4CKDM2ATET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| US-20250375544-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2025-12-11 | — | — | US | disclosed |
| EP-4271422-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | Technische Universität München (DE) | 2023-11-08 | — | — | EP | disclosed |
| CN-116981486-A | Dual mode radiotracer and therapeutic agent | 慕尼黑工业大学 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022144467-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | Technische Universität München (DE) | 2022-07-07 | — | — | WO | disclosed |
| EP-4023250-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | Technische Universität München (DE) | 2022-07-06 | — | — | EP | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| US-10053468-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| EP-3018126-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-0467280-A1 | Novel spergualin-related compound and use thereof | Nippon Kayaku Kabushiki Kaisha (JP) | 1992-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053468-B2 | Heterocyclic compound | RORC, RORB, RORA | TET2 570/4885KDM4A 744/4885KDM4C 927/4885 |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | TET2 570/4885KDM4A 744/4885KDM4C 927/4885 |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | TET2 4875/4885KDM4A 3215/4885KDM4C 2542/4885 |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | TET2 570/4885KDM4A 744/4885KDM4C 927/4885 |
| US-20250375544-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | MAN2B1, GBA1, SSTR1 | TET2 4722/4885KDM4A 2839/4885KDM4C 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.